3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Breast Neoplasms
4
Recurrence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Diseases
1
Anemia
1
Amyloidosis
1
Interventions
Rituximab
5
Lenalidomide
3
fludarabine
2
Cyclophosphamide
2
zanubrutinib
1
venetoclax
1
umbralisib
1
ublituximab
1
tisagenlecleucel
1
tazemetostat
1
tafasitamab
1
prednisolone phosphate
1
prednisolone acetate
1
pirtobrutinib
1
obinutuzumab
1
duvelisib
1
axicabtagene ciloleucel
1
Prednisolone
1
Methylprednisolone
1
Bendamustine Hydrochloride
1
Appointments and Schedules
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Lymphoma, Follicular
×
Cyclophosphamide
×
Clear all
NCT03105336
2025-12-23
ZUMA-5
Gilead Sciences
Phase 2
Completed
159 enrolled
27 charts
1 FDA
NCT04245839
2025-11-05
TRANSCEND FL
Celgene
Phase 2
Active not recruiting
276 enrolled
2 FDA